-
Mashup Score: 2
Nature – Type 1 regulatory T cells (Tr1) represent a major obstacle that compromises naturally occurring and therapeutically induced tumour-specific immunity.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Personalized cancer vaccine: Researchers in Pittsburgh discuss possible future breakthrough - 1 year(s) ago
Vaccine could soon change cancer treatment
Source: www.wtae.comCategories: General Medicine News, Hem/OncsTweet-
Appreciated op to discuss rapidly advancing research on personalized #cancer vaccines w @MichelleWTAE @WTAE & how @UPMCHillmanCC is at the forefront leading international clinical trials for individualized neoantigen therapies in #melanoma & other cancers! https://t.co/V8eRhByNuC https://t.co/H2hVFiOnPW
-
-
Mashup Score: 21Top advances of the year: Melanoma - 1 year(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Hem/OncsTweet-
Top advances of the year #Melanoma! Great work @AdnanKhattakOnc on impact of TIL approval, novel strategies targeting PRAME, oncolytic virus as well as neo-/adjuvant strategies such as mRNA individualized neoAg therapy. Quick read to stay UTD! https://t.co/4aaPPh174w https://t.co/uzinJJmRfx
-
-
Mashup Score: 21Top advances of the year: Melanoma - 1 year(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Hem/OncsTweet-
Top advances of the year #Melanoma! Great work @AdnanKhattakOnc on impact of TIL approval, novel strategies targeting PRAME, oncolytic virus as well as neo-/adjuvant strategies such as mRNA individualized neoAg therapy. Quick read to stay UTD! https://t.co/4aaPPh174w https://t.co/uzinJJmRfx
-
-
Mashup Score: 11
The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are calling on manufacturers of diagnostics and therapeutics to adopt therapeutic group labeling to
Source: society.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Along with Dr. Jordan Laser, excited to present @ASCO @Pathologists statement on group labeling. Important effort w diverse committee of academia, industry & patient advocacy input. As a field, let's simplify things to improve research & patient care! https://t.co/ECpiCT7EIJ https://t.co/qk1hGQyCdr
-
-
Mashup Score: 34
Background Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their potential, these therapies have had limited success in late-phase trials for advanced cancer resulting in few formal approvals. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to determine how to design clinical trials with the greatest chance of demonstrating the benefits of intratumoral immunotherapy for patients with cancers across all stages of pathogenesis. Methods An Intratumoral Immunotherapy Clinical Trials Expert Panel composed of international key stakeholders from academia and industry was assembled. A multiple choice/free response survey was distributed to the panel, and the results of this survey were discussed during a half-day consensus meeting. Key discussion points are summarized in the follow
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Excited to present @sitcancer guidelines for clinical research on intra-tumoral #immunotherapy. This was a collaborative effort from expert stakeholders across academia & industry. Tremendous potential from pre- to advanced cancer for novel agents. https://t.co/xmEeRzhk7z https://t.co/P5va0YABQw
-
-
Mashup Score: 41
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Pembrolizumab adjuvant therapy was shown to significantly improve recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB or IIC melanoma in earlier analyses of the randomized, double-blind, phase III KEYNOTE-716 study (ClinicalTrials.gov identifier: NCT03553836). We report results of the protocol-specified final analysis of DMFS for KEYNOTE-716. Overall, 976 patients were randomly allocated to pembrolizumab (n = 487) or placebo (n = 489). As of January 4, 2023, median follow-up was 39.4 months (range, 26.0-51.4 mont
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
3 year update for KN716 now online @JCO_ASCO. Foundational data for adjuvant #melanoma emphasizing patients with stage IIB/C dz are at high risk & anti-PD1 is highly effective to prevent recurrence. Next step - biomarker work to optimize patient selection! https://t.co/cI55QkTwmE https://t.co/XmWMWAHr1i
-
-
Mashup Score: 27Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Field of #melanoma therapeutics is moving fast, esp in the operative space. Another great effort from @RyanAugustinMD overviewing neo-/adjuvant therapy, on-going clinical trials that will impact care, role of nodal eval, biomarkers & next steps https://t.co/rIAuWbxLBx https://t.co/VPaMQcc8gN
-
-
Mashup Score: 59Deep whole-genome analysis of 494 hepatocellular carcinomas - 1 year(s) ago
Nature – The Chinese Liver Cancer Atlas project depicts a panoramic genomic landscape of hepatocellular carcinoma, covering candidate coding and non-coding drivers, mutational signatures,…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @Nature: Nature research paper: Deep whole-genome analysis of 494 hepatocellular carcinomas https://t.co/2OP2xFE5nD
-
-
Mashup Score: 5Revolution in the next KRAS battleground - 1 year(s) ago
With Revolution Medicines initiating dosing in the first-in-human study of its KRAS G12D inhibitor RMC-9805, the industry pipeline now comprises six clinical-stage projects with this modality. If the KRAS G12C space, now featuring the approved drugs Lumakras from Amgen and Krazati from Mirati, fast became crowded, then that targeting KRAS G12D-driven tumours might follow suit, given that G12D is…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: KRAS G12D is crowded! https://t.co/QFoSnRLSvD https://t.co/VxZHQncGo6
-
RT @SMImmunology: Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy https://t.co/aMQzIiXLMP